Skip to main content

Before you download

We use your information to keep you updated on kidney health matters of interest to you. We will only ask you once and then you’ll be able to seamlessly download resources as you need. You are free to unsubscribe from our communications at any time.

Find out how we protect your information in our Privacy Policy.

A phase 1/2A dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Aro-C3 in adult healthy volunteers and in adult patients with complement-mediated renal disease

Brief Description:

The ARO-C3 study is sponsored by Arrowhead Pharmaceuticals, Inc. and is developing ARO-C3 to treat complement-mediated renal diseases (C3G and IgA Nephropathy). ARO-C3 works by blocking production of the complement component 3 (C3) protein in the liver. C3 plays a role in activating the complement cascade in the body's immune system, which can lead to kidney injury from excessive or unsuitable activation of the complement system. ARO-C3 will be administered by subcutaneous injection on Days 1, 29 and 113 of the study.

Type of research:

Clinical Trial

Your time commitment:


Consumers re-imbursed?

Expenses covered

Participants will receive $250 per study visit as compensation for inconvenience, loss of wages and family care costs while attending study visits. Study participants will also receive reimbursement for travel, parking, meals and other expenses associated with study visits.

Who are researchers looking for?

Person with early stage kidney disease

Contact for more info:

Email: [email protected]

Return to research listing page